Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by RoyaleWithCheezon Nov 23, 2021 3:24pm
223 Views
Post# 34158498

From the Q3 report

From the Q3 report
I'm wishing anyone involved in the lawsuit good luck , but is +/- 90% of your claim based on 'future value' of the shares?  That may be a challenge.  

From the Q3 report:
Legal proceedings 
The Company is, in the course of its business, subject to lawsuits and other claims. On April 15, 2019, the 
Company announced its intention to enter into a series of related arrangements to restructure its outstanding 
indebtedness, reduce its interest and certain other payment obligations, and raise sufficient cash to build a 
robust balance-sheet for the next phase of its development (collectively, the “Refinancing Transactions”). 
 
On March 2, 2021, Liminal was served with an action instituted by multiple individual shareholder plaintiffs (the 
“Plaintiffs”) against Liminal, SALP, Thomvest, Consonance Capital Management LP (“Consonance”), as well the 
directors (the “Directors”) that were on the Company’s Board on March 31, 2019 or on April 15, 2019 and certain 
officers of the Company (the “D&Os”, together with Liminal, SALP, Thomvest and Consonance, the 
“Defendants”). Such action was publicly disclosed on March 24, 2021. On November 2, 2021, Liminal received 
service of an amended proceeding. 
 
The Plaintiffs’s request in damages has gone from almost $700 million initially to almost $950 million in 
damages, approximately $905 million of which is based on the loss of future value of the Company’s shares. 
 
The Company believes that the Plaintiffs’ claims are completely without merit and intends to vigorously defend 
itself. Defense and settlement costs associated with such lawsuits and claims can be substantial, even when 
these lawsuits and claims have no merit. Due to the inherent uncertainty of the litigation process, the resolution 
of any particular legal proceeding could have an adverse effect on the Company’s operating results or financial 
performance. No provisions have been recorded in the interim financial statements in regards to these claims.
<< Previous
Bullboard Posts
Next >>